High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease
Ebach D, Jester T, Galanko J, Firestine A, Ammoury R, Cabrera J, Bass J, Minar P, Olano K, Margolis P, Sandberg K, Linnville T, Kaplan J, Pitch L, Steiner S, Bass D, Moses J, Adler J, Gulati A, Wali P, Pashankar D, Ivanova A, Herfarth H, Wohl D, Benkov K, Strople J, Sullivan J, Tung J, Molle-Rios Z, Saeed S, Bousvaros A, Kappelman M. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease. The American Journal Of Gastroenterology 2024, 119: 1110-1116. PMID: 38445644, PMCID: PMC11150092, DOI: 10.14309/ajg.0000000000002741.Peer-Reviewed Original ResearchHigher body mass indexNormal body mass indexPediatric Crohn's diseaseBody mass indexAnti-TNF levelsInfliximab initiationTrough levelsTreatment failureObese patientsMass indexTime-to-treatment failureCrohn's diseaseResponse to anti-TNF therapyAssociated with treatment failureMonotherapy to combination therapyBody mass index groupsBody mass index categoriesPrescribed anti-TNFProactive drug monitoringAdalimumab-treated patientsDrug trough levelsAnti-TNF treatmentAnti-TNF therapyInfliximab trough levelsWeight-based dosing